Therapeutic Asset Ratings
622 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
her2 vaccine
Breast Cancer
Pravin T.P Kaumaya
P1
C
(36)
HUMAN FAECAL MATTER
Breast Cancer
M.D. Anderson Cancer Center
P1
C
(36)
ic9-car.b7-h3 t cell therapy
Breast Cancer
UNC Lineberger Comprehensive Cancer Center
P1
C
(36)
Ide-161
Breast Cancer
IDEAYA Biosciences
P1
C
(36)
Idov-Immune
Breast Cancer
ViroMissile, Inc.
P1
C
(36)
iks014
Breast Cancer
Iksuda Therapeutics Ltd.
P1
C
(36)
il-15 enhanced engineered nk cells
Breast Cancer
M.D. Anderson Cancer Center
P1
C
(36)
im-1617
Breast Cancer
Immunome, Inc.
P1
C
(36)
imm2520
Breast Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
P1
C
(36)
iopofosine (¹³¹I)
Breast Cancer
Cellectar Biosciences, Inc.
P1
C
(36)
kj015
Breast Cancer
Shanghai Bao Pharmaceuticals Co., Ltd.
P1
C
(36)
Kk-Lc-1 Tcr-T Cells
Breast Cancer
Christian Hinrichs
P1
C
(36)
Kras Tcr-Transduced Pbl
Breast Cancer
National Cancer Institute (NCI)
P1
C
(36)
Lncb74
Breast Cancer
NextCure, Inc.
P1
C
(36)
Loxo-783
Breast Cancer
Eli Lilly and Company
P1
C
(36)
L-TRYPTOPHAN, 1-(2-(FLUORO-18F)ETHYL)-
Breast Cancer
Barbara Ann Karmanos Cancer Institute
P1
C
(36)
Lutetium [177Lu] Bl-Arc001
Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
P1
C
(36)
Mbq-167
Breast Cancer
MBQ Pharma
P1
C
(36)
Mesothelin-Targeted T Cells
Breast Cancer
Memorial Sloan Kettering Cancer Center
P1
C
(36)
MGC026
Breast Cancer
MacroGenics
P1
C
(36)
Moma-313
Breast Cancer
MOMA Therapeutics
P1
C
(36)
ngm438
Breast Cancer
NGM Biopharmaceuticals, Inc
P1
C
(36)
ngm831
Breast Cancer
NGM Biopharmaceuticals, Inc
P1
C
(36)
Nuv-868
Breast Cancer
Nuvation Bio Inc.
P1
C
(36)
Oct-598
Breast Cancer
Oscotec Inc.
P1
C
(36)
Showing 501 to 525 of 622 assets
Previous
Page 21 of 25
Next